News
CEREW
18.07
-3.27%
-0.61
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 04/18 16:32
BUZZ-U.S. STOCKS ON THE MOVE-D.R. Horton, 23andMe, Copper miners
D.R. Horton, 23andMe, Copper miners rise as chip stocks rebound. Dow e-minis expected to open higher on Thursday. Investors await commentary from Federal Reserve officials on outlook for interest-rate cuts. 23andme rises after CEO considers taking firm private.
Reuters · 04/18 13:13
BUZZ-Cerevel rises as Parkinson's drug improves symptom control in late-stage trial
Shares of drug developer Cerevel Therapeutics rise 1.4% to $42.20 premarket. Cerevel says Parkinson's drug improves symptom control in late-stage trial. Company says drug tavapadon improved symptoms control in Parkinson's disease patients.
Reuters · 04/18 12:10
UPDATE 1-Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study
Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study. Trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson's. Cerevel's drug met the main goal of a late stage trial.
Reuters · 04/18 10:51
UPDATE 2-Cerevel's Parkinson's disease drug improves symptom control in late-stage trial
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial. Drug tested as an add-on therapy to levodopa. The disease affects about 1 million people in the United States. AbbVie agreed to buy Cerevel Therapeutics in December for $8.7 billion.
Reuters · 04/18 10:51
CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATED
Reuters · 04/18 10:30
BUZZ-Moody's says pharma outlook turns 'positive' on GLP-1 drug push
Moody's says outlook for U.S. Pharmaceutical credit to "positive" from "stable" on GLP-1 and other blockbuster drugs push. Positive outlook reflects expectations of 4%-6% annual core earnings growth over the 12-18 months. Industry growth will benefit from rising use of blockbuster drugs.
Reuters · 03/14 14:35
UPDATE 1-AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports
AbbVie looking to sell at least $13 billion of corporate bonds to fund M&A, Bloomberg reports. The sale is expected to be announced as soon as Thursday, the report says. The drugmaker is looking to fund its acquisitions of ImmunoGen and Cerevel Therapeutics.
Reuters · 02/21 23:41
Abbvie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports
Abbvie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports. The company is looking to sell bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics. AbbVie to sell corporate bonds to raise money to fund acquisitions, Bloomberg says.
Reuters · 02/21 23:02
Cerevel Therapeutics Holdings Inc <CERE.OQ> expected to post a loss of 59 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 59 cents a share. The company is expected to show change in quarterly revenue when it reports results on February 20. Average analyst rating on the shares is "hold" and the median 12-month price target is $45.
Reuters · 02/16 13:55
UPDATE 1-AbbVie profit beats on better-than-expected Humira, Botox sales
AbbVie profit beats on better-than-expected Humira, Botox sales. Humira's sales fell 41% to $3.30 billion in the fourth quarter, but beat estimates. The company reported a quarterly adjusted profit of $2.79 per share.
Reuters · 02/02 13:16
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals. Humira's sales fell 41% to $3.30 billion in the fourth quarter. Strong demand for Botox amid stiff competition. The company beat Wall Street estimates for fourth-quarter profit.
Reuters · 02/02 12:36
U.S. RESEARCH ROUNDUP- Cerevel Therapeutics, Cytokinetics, Karuna Therapeutics
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Cerevel Therapeutics, Cytokinetics, Karuna Therapeutic and Microsoft among those. Analysts raise their ratings and target prices on several companies. The companies include Cerevel, Cy tokinetics and Karuna.
Reuters · 12/28/2023 06:42
U.S. RESEARCH ROUNDUP- Atlassian Corp, Broadcom, Cerevel Therapeutics Holdings
Wall street analysts revise ratings and price targets on several u.s.-listed companies. Atlassian corp, broadcom, cerevel therapeutics holdings among companies with revised targets. Abbvie, gms and others also see analyst upgrades and downgrades. Analysts also raise or lower target prices on several companies.
Reuters · 12/08/2023 07:07
BUZZ-U.S. STOCKS ON THE MOVE-Canadian Solar, Domino's, tech stocks
The nasdaq outpaced other major wall street indexes on thursday as alphabet shares surged. The dow jones industrial average was up 0.26%, the s&p 500 and the nasdaq were all up. Alphabet shares jumped 5.5% as the company reported better-than-expected results.
Reuters · 12/07/2023 18:58
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say
Abbvie's $8.7 bln bet on cerevel is risky but smart, analysts say. Buying cerevel before key data on its schizophrenia drug could have avoided a bidding war, they say. Cerevel's schizophrenia drug trials have a high chance of failure, but the deal is "de-risked" abbvie's deal with cerevel avoids a possible bidding war but comes with risks, analysts said.
Reuters · 12/07/2023 18:30
Bain scores over tenfold return with $8.7 billion Cerevel sale
Bain committed $250 million in 2018 to invest in drug developer cerevel therapeutics holdings. Bain scored over tenfold return with $8.7 billion sale to abbvie, regulatory filings show. Bain's 36.5% stake in cerevel is valued at about $2.7billion.
Reuters · 12/07/2023 17:35
BUZZ-Karuna Therapeutics falls as rival Cerevel snapped up by AbbVie
Karuna therapeutics shares fall 2.9% to $202.7 in morning trade. Abbvie says it will buy rival cerevel for $8.7 bln. Stock set for biggest one-day drop in a month as shares of rival krtx fall.
Reuters · 12/07/2023 16:15
BUZZ-U.S. STOCKS ON THE MOVE-Veeva systems, Alphabet, Moderna
The nasdaq led gains among wall street's major indexes on thursday. The dow jones industrial average was up 0.14% at 36,103.73. Alphabet shares rose 5.3% and advanced micro device up 5.9%. Veeva systems, alphabet, moderna among the day's losers in the u.s.
Reuters · 12/07/2023 16:01
More
Webull provides a variety of real-time CEREW stock news. You can receive the latest news about CEREVEL THERAPEU through multiple platforms. This information may help you make smarter investment decisions.
About CEREW
Cerevel Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company. The Company combines understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies. The Company has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. The Company’s pipeline includes Tavapadon, CVL-871, CVL-865, CVL-231 and CVL-936.